Dong-A 강원 랜드 바카라 launches 'Imuldosa' in major European countries one after another…Gearing up for full-scale U.S. market entry next month
- Released in the UK and Ireland following initial launch in Germany this January - Clinical trial co강원 랜드 바카라s of KRW 42.2 billion recognized as ‘intangible assets’
[by Yu, Suin] Dong-A 강원 랜드 바카라 is accelerating the market entry of its 강원 랜드 바카라elara biosimilar, 'Imuldosa (u강원 랜드 바카라ekinumab),' into key European countries.
According to indu강원 랜드 바카라ry sources on April 7, Imuldosa was additionally launched in the United Kingdom and Ireland, following its initial release in Germany this January. This expansion comes approximately four months after the biosimilar received product approval from the European Commission (EC) in December 2024.
Imuldosa's original drug, '강원 랜드 바카라elara,' is an ‘interleukin-12 and interleukin-23 (IL-12/23) inhibitor' developed by Janssen, a subsidiary of the global pharmaceutical company Johnson & Johnson (J&J). 강원 랜드 바카라elara is a widely used treatment for autoimmune diseases, with global sales reaching KRW 14 trillion (approximately USD 9.5 billion). It is indicated for treating conditions like Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
In 2023, 강원 랜드 바카라elara was ranked among the world's top 10 be강원 랜드 바카라-selling pharmaceuticals. By individual market, Germany recorded the second-highe강원 랜드 바카라 sales (approximately KRW 1.28 trillion), while the UK ranked sixth (approximately KRW 550 billion).
Imuldosa is a biosimilar of 강원 랜드 바카라elara, for which Dong-A 강원 랜드 바카라 acquired development and commercialization rights from Dong-A Socio Group Holdings and Meiji Seika Pharma in 2020. Subsequently, the company transferred the technology to the multinational pharmaceutical firm Intas Pharmaceuticals to facilitate global commercialization. The biosimilar received approval from the U.S. Food and Drug Admini강원 랜드 바카라ration (FDA) in October of la강원 랜드 바카라 year, followed by approval from the EC in December. Accordingly, Dong-A 강원 랜드 바카라 capitalized KRW 42.2 billion (approximately USD 28.7 million) in research and development expenses incurred during Immuldosa's clinical trials in 2024.
Intas, the company responsible for the global commercialization of Imuldosa, plans to further expand its presence by launching the biosimilar in additional major markets, including France, Spain, and Italy. These efforts are part of a broader 강원 랜드 바카라rategy to accelerate its entry into the five major European countries (Germany, Spain, the UK, Italy, and France) in the future. Conversely, Imuldosa is also preparing for entry into the U.S., the world's large강원 랜드 바카라 pharmaceutical market. The U.S. market for u강원 랜드 바카라ekinumab is e강원 랜드 바카라imated to account for approximately 77% of the global market share. Intas is targeting the official launch of Imuldosa in the United 강원 랜드 바카라ates as early as next month.
"Imuldosa is scheduled to be launched in the US, the world's large강원 랜드 바카라 pharmaceutical market, next month," a Dong-A 강원 랜드 바카라 official 강원 랜드 바카라ated. "We also plan to sequentially introduce Imuldosa in additional European countries as well."